Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last

Catherine Le Berre; Amanda Ricciuto; Laurent Peyrin-Biroulet; Dan Turner

doi:10.1053/j.gastro.2021.09.076

Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last

Catherine Le Berre, Amanda Ricciuto, Laurent Peyrin-Biroulet, Dan Turner^*

^*Corresponding author for this work

Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Short- and long-term treatment targets in inflammatory bowel diseases (IBDs) evolved during the last decade, shifting from symptom control to endoscopic healing and patient-centered parameters. The STRIDE-II consensus placed these targets on a timeline from initiating treatment and introduced additional targets, normalization of serum and fecal biomarkers, restoration of quality of life, prevention of disability, and, in children, restoration of growth. Transmural healing in Crohn's disease and histologic healing in ulcerative colitis currently serve as adjunct measures to gauge remission depth. However, whether early treatment according to a treat-to-target paradigm affects the natural course of IBD remains unclear, leading to the need for prospective disease-modification trials. The SPIRIT consensus defined the targets for these trials to assess the long-term impact of early treatment on quality of life, disability, disease complications, risk of neoplastic lesions, and mortality. As further data emerge about the risk-benefit balance of aiming toward deeper healing, the targets in treating IBDs may continue to shift.

Original language	American English
Pages (from-to)	1424-1438
Number of pages	15
Journal	Gastroenterology
Volume	162
Issue number	5
DOIs	https://doi.org/10.1053/j.gastro.2021.09.076
State	Published - Apr 2022

Bibliographical note

Funding Information:
Conflicts of interest CLB declares no conflict of interest relevant to this article. AR declares no conflicts of interest. LPB reports personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher; grants from AbbVie , MSD , Takeda , Fresenius Kabi; stock options: CTMA. DT has received consultation fees, research grants, royalties, or honoraria from Janssen, Pfizer, The Hospital for Sick Children, Ferring, AbbVie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, and BMS.

Funding Information:
Conflicts of interest CLB declares no conflict of interest relevant to this article. AR declares no conflicts of interest. LPB reports personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher; grants from AbbVie, MSD, Takeda, Fresenius Kabi; stock options: CTMA. DT has received consultation fees, research grants, royalties, or honoraria from Janssen, Pfizer, The Hospital for Sick Children, Ferring, AbbVie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, and BMS.

Publisher Copyright:
© 2022 AGA Institute

Keywords

Disease Control
Disease Modification
Natural History
Therapeutic Goals
Prospective Studies
Humans
Inflammatory Bowel Diseases/pathology
Quality of Life
Colitis, Ulcerative/diagnosis
Goals
Child
Remission Induction

Access to Document

10.1053/j.gastro.2021.09.076

Cite this

@article{8ebd4a6726e24d83a6bfda0bb7f5b8b4,

title = "Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last",

abstract = "Short- and long-term treatment targets in inflammatory bowel diseases (IBDs) evolved during the last decade, shifting from symptom control to endoscopic healing and patient-centered parameters. The STRIDE-II consensus placed these targets on a timeline from initiating treatment and introduced additional targets, normalization of serum and fecal biomarkers, restoration of quality of life, prevention of disability, and, in children, restoration of growth. Transmural healing in Crohn's disease and histologic healing in ulcerative colitis currently serve as adjunct measures to gauge remission depth. However, whether early treatment according to a treat-to-target paradigm affects the natural course of IBD remains unclear, leading to the need for prospective disease-modification trials. The SPIRIT consensus defined the targets for these trials to assess the long-term impact of early treatment on quality of life, disability, disease complications, risk of neoplastic lesions, and mortality. As further data emerge about the risk-benefit balance of aiming toward deeper healing, the targets in treating IBDs may continue to shift.",

keywords = "Disease Control, Disease Modification, Natural History, Therapeutic Goals, Prospective Studies, Humans, Inflammatory Bowel Diseases/pathology, Quality of Life, Colitis, Ulcerative/diagnosis, Goals, Child, Remission Induction",

author = "{Le Berre}, Catherine and Amanda Ricciuto and Laurent Peyrin-Biroulet and Dan Turner",

note = "Funding Information: Conflicts of interest CLB declares no conflict of interest relevant to this article. AR declares no conflicts of interest. LPB reports personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher; grants from AbbVie , MSD , Takeda , Fresenius Kabi; stock options: CTMA. DT has received consultation fees, research grants, royalties, or honoraria from Janssen, Pfizer, The Hospital for Sick Children, Ferring, AbbVie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, and BMS. Funding Information: Conflicts of interest CLB declares no conflict of interest relevant to this article. AR declares no conflicts of interest. LPB reports personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher; grants from AbbVie, MSD, Takeda, Fresenius Kabi; stock options: CTMA. DT has received consultation fees, research grants, royalties, or honoraria from Janssen, Pfizer, The Hospital for Sick Children, Ferring, AbbVie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, and BMS. Publisher Copyright: {\textcopyright} 2022 AGA Institute",

year = "2022",

month = apr,

doi = "10.1053/j.gastro.2021.09.076",

language = "American English",

volume = "162",

pages = "1424--1438",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders Ltd",

number = "5",

}

TY - JOUR

T1 - Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases

T2 - Getting It Right, Making It Last

AU - Le Berre, Catherine

AU - Ricciuto, Amanda

AU - Peyrin-Biroulet, Laurent

AU - Turner, Dan

N1 - Funding Information: Conflicts of interest CLB declares no conflict of interest relevant to this article. AR declares no conflicts of interest. LPB reports personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher; grants from AbbVie , MSD , Takeda , Fresenius Kabi; stock options: CTMA. DT has received consultation fees, research grants, royalties, or honoraria from Janssen, Pfizer, The Hospital for Sick Children, Ferring, AbbVie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, and BMS. Funding Information: Conflicts of interest CLB declares no conflict of interest relevant to this article. AR declares no conflicts of interest. LPB reports personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher; grants from AbbVie, MSD, Takeda, Fresenius Kabi; stock options: CTMA. DT has received consultation fees, research grants, royalties, or honoraria from Janssen, Pfizer, The Hospital for Sick Children, Ferring, AbbVie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, and BMS. Publisher Copyright: © 2022 AGA Institute

PY - 2022/4

Y1 - 2022/4

N2 - Short- and long-term treatment targets in inflammatory bowel diseases (IBDs) evolved during the last decade, shifting from symptom control to endoscopic healing and patient-centered parameters. The STRIDE-II consensus placed these targets on a timeline from initiating treatment and introduced additional targets, normalization of serum and fecal biomarkers, restoration of quality of life, prevention of disability, and, in children, restoration of growth. Transmural healing in Crohn's disease and histologic healing in ulcerative colitis currently serve as adjunct measures to gauge remission depth. However, whether early treatment according to a treat-to-target paradigm affects the natural course of IBD remains unclear, leading to the need for prospective disease-modification trials. The SPIRIT consensus defined the targets for these trials to assess the long-term impact of early treatment on quality of life, disability, disease complications, risk of neoplastic lesions, and mortality. As further data emerge about the risk-benefit balance of aiming toward deeper healing, the targets in treating IBDs may continue to shift.

AB - Short- and long-term treatment targets in inflammatory bowel diseases (IBDs) evolved during the last decade, shifting from symptom control to endoscopic healing and patient-centered parameters. The STRIDE-II consensus placed these targets on a timeline from initiating treatment and introduced additional targets, normalization of serum and fecal biomarkers, restoration of quality of life, prevention of disability, and, in children, restoration of growth. Transmural healing in Crohn's disease and histologic healing in ulcerative colitis currently serve as adjunct measures to gauge remission depth. However, whether early treatment according to a treat-to-target paradigm affects the natural course of IBD remains unclear, leading to the need for prospective disease-modification trials. The SPIRIT consensus defined the targets for these trials to assess the long-term impact of early treatment on quality of life, disability, disease complications, risk of neoplastic lesions, and mortality. As further data emerge about the risk-benefit balance of aiming toward deeper healing, the targets in treating IBDs may continue to shift.

KW - Disease Control

KW - Disease Modification

KW - Natural History

KW - Therapeutic Goals

KW - Prospective Studies

KW - Humans

KW - Inflammatory Bowel Diseases/pathology

KW - Quality of Life

KW - Colitis, Ulcerative/diagnosis

KW - Goals

KW - Child

KW - Remission Induction

UR - http://www.scopus.com/inward/record.url?scp=85127258487&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2021.09.076

DO - 10.1053/j.gastro.2021.09.076

M3 - Article

C2 - 34995529

AN - SCOPUS:85127258487

SN - 0016-5085

VL - 162

SP - 1424

EP - 1438

JO - Gastroenterology

JF - Gastroenterology

IS - 5

ER -

Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this